The European Medicines Agency (EMA) will allow Actos, to remain on the market in Europe, with more serious warnings regarding potential bladder cancer risks. Actos is Takeda Pharmaceutical’s controversial Type 2 diabetes drug. A report from the EMA’s Committee for Medicinal Products for Human Use determined that
Read more →
Recent Comments